Antiepileptic drugs in psychiatry

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 12, 2004, Pages 1655-1658

  Osview, F ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; ESCITALOPRAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OXCARBAZEPINE; SERTRALINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VALPROMIDE; VITAMIN D;

AGITATION; ANOMIA; ANTICONVULSANT THERAPY; ANXIETY DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY WEIGHT; BONE DENSITY; BORDERLINE STATE; BULIMIA; COGNITIVE DEFECT; DYSLIPIDEMIA; EDITORIAL; ENDOCRINE DISEASE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; LEARNING DISORDER; LIVER TOXICITY; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; OSTEOLYSIS; OVARY POLYCYSTIC DISEASE; PARKINSONISM; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; PSYCHIATRY; QUALITY OF LIFE; RISK ASSESSMENT; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 10044259990     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.036863     Document Type: Editorial

References (70)

1. Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004;328(7451):1273-4.
2. Post RM. Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms? Epilepsy Res 2002;50(1-2):203-19.
3. Ketter TA, Wang PW, Becker OV, et al. The diverse roles of anticonvulsants in bipolar disorders. Ann Clin Psychiatry 2003;15(2):95-108.
4. Harris M, Chandran S, Chakraborty N, et al. Mood-stabilizers: the archaeology of the concept. Bipolar Disord 2003;5(6):446-52.
5. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ 2004;328(7450):1217.
6. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161(1):3-8.
7. Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159(6):1005-10.
8. Angst J, Gamma A, Benazzi F, et al. Toward a redefinition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003;73(1-2):133-46.
9. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsycnopnarmacol 2003;6(2):127-37.
10. Muzina DJ, El-Sayegh S, Calabrese JR. Antiepileptic drugs in psychiatry-focus on randomized controlled trial. Epilepsy Res 2002;50(1-2):195-202.
11. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004,79(1-3):273-7.
12. Centorrino F, Albert MJ, Berry JM, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003;5(5):370-4.
13. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001;2(1):28-36.
14. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41.
15. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmocol 2002;22(6)599-609.
16. Bräunig P, Kruger S. Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 2003;17(2):239-41.
17. Grunze H, Langosch J, Born C, et al. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003;64(7):781-4.
18. Kanba S, Yogi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994;18(4):707-15.
19. Schaffer LC, Schaffer CB, Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002;71(1-3):259-63.
20. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 Pt 2):249-55.
21. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20(6):607-14.
22. Martínez-Rogo J, Sabater A, Perez-Galvez B, et al. Add-on gabapentín in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(3):599-601.
23. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD; a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001;13(3):141-6.
24. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20(4):467-71.
25. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 2002;16(5):291-302.
26. Zarate CA Jr, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry 1997;9(1):19-25.
27. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54(11):1241-8.
28. Hosák L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002;17(7):371-8.
29. Perugi G, Toni C, Travierso MC, et al. The role of cyclothymia in atypical depression: toward a data-based reconceptualization of the borderline-bipolar II connection. J Affect Disord 2003;73(1-2):87-98.
30. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986;143(4):519-22.
31. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51(3):333-43.
32. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28(6):1186-97.
33. Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug DeliV Rev 2002;54(12):1567-77.
34. Lonergan E, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004;(2):CD003945.
35. Kanner AM. Psychiatric comorbidity in patients with developmental disorders and epilepsy: a practical approach to its diagnosis and treatment. Epilepsy Behav 2002;3(6S1):7-13.
36. Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003;20(14):1035-40.
37. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37(3):193-220.
38. Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55(5):729-32.
39. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17(11):781-91.
40. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003;64(12):1449-54.
41. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003;64(11):1335-41.
42. Gadde KM, Franciscy DM, Wagner HR 2nd, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289(14):1820-5.
43. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J Clin Psychopharmacol 2004;24(3):322-34.
44. Harden CL. What valproate does and doesn't do. Epilepsy Currents 2004;4(2):59-60.
45. Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42(8):1002-6.
46. McIntyre RS, Mancini DA, McCann S, et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5(1):28-35.
47. Morrell MJ, Isojarvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54(2-3):189-99.
48. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology2004;145(2):799-808.
49. Akdeniz F, Taneli F, Noyan A, et al. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry 2003;27(1):115-21.
50. Isojärvi JI, Löfgren E, Juntunen KS, et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004;62(2):247-53.
51. Bauer J, Blumenthal S, Reuber M, et al. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology 2004;62(2):243-6.
52. Boylan LS, Devinsky O, Barry JJ, et al. Psychiatric uses of antiepileptic treatments. Epilepsy Behav 2002;3(55):54-9.
53. Gardner DL, Cowdry RW. Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol 1986;6(4):236-9.
54. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004;13(1):55-7.
55. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61(5):704-6.
56. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in potients with epilepsy. Epilepsia 2003;44(5):659-63.
57. Bootsma HP, Coolen F, Aldenkamp AP, et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2004;5(3):380-7.
58. Kockelmann E, Elger CE, Helmstaedter C Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003;54(2-3):171-8.
59. Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003;44(12):1573-7.
60. Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003;4(4):430-4.
61. Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4(2):124-32.
62. Easterford K, Clough P, Kellett M, et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004;62(8):1435-7.
63. Iijima M. Valproate-induced parkinsonism in a demented elderly potient. J Clin Psychiatry 2002;63(1):75.
64. Wils V, Goluke-Willemse G. Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in on elderly manic patient, Int J Geriatr Psychiatry 1997;12(2):272.
65. Ali II, Schuh L, Barkley GL, et al. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav 2004;5(3):296-300.
66. Heller HJ, Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neural 2001;58(9):1352-3.
67. McGuire JM, Baram V, Asher JM. Osteopenia associated with divalproex sodium. J Clin Psyopharmacol 2004;24(3):357-8.
68. Cramer JA, Blum D, Reed M, et al. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003;4(5):515-21.
69. Boylan LS, Flint LA, Labovitz DL, et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004;62(2):258-61.
70. De Leon J. Psychopharmocology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv 2004;55(2):125-8.